Type 2 Diabetes

The TMIOA Medical Director highlights the best sessions, new topics, and growing discussion around the 18th annual congress.

Intervention participants had significant reductions in weight and HbA1c but there were no differences in hospital admissions or health care spending.

An analysis of the Look AHEAD study by investigators at Johns Hopkins details associations between long-term variability of glycemic markers and increased risk of all-cause and cardiovascular mortality.

Pediatric patients who initiated insulin pump therapy within 6 months of diagnosis demonstrated better cardiovascular risk profiles than those who delayed treatment.

With the prevalence of diabetes continuing to grow, Gregory Weiss, MD, reflects on his experience treating patients with diabetes as a cardiologist and how recent advances have impacted cardiology.

An analysis of data from more than 25k women suggests greater adherence to a Mediterranean diet was linked to a lower risk of developing diabetes.

In this 3-part feature series, an endocrinologist, a cardiologist, and an internist tackle the topic of who should be in charge of treating patients with diabetes and whether the creation of a cardiometabolic specialty is a worthwhile endeavor.

Literature is scarce in identifying and characterizing risk of post-operative diabetes mellitus among patients with pancreatic cystic lesions.

In this 3-part feature series, an endocrinologist, a cardiologist, and an internist tackle the topic of who should be in charge of treating patients with diabetes and whether the creation of a cardiometabolic specialty is a worthwhile endeavor.

In the last of our 3-part series examining the idea of a cardiometabolic subspecialty, Simon Murray, MD, offers his thoughts on who should be treating patients with type 2 diabetes.

More studies are planned testing the impact of finerenone.

An endocrinologist from Brigham and Women’s Hospital discusses the latest in diabetes management.

Finerenone could be another option to SGLT2 inhibitors for this patient population.

About 20% of 81 positive patients experienced critical neurological complications; further, half had a pre-existing history of high blood pressure or type 2 diabetes.

Researchers present new data from the SUSTAIN 6 and PIONEER 6 trials during the virtual AHA 2020 conference.

The indication comes from collaborative work among experts and community leaders coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.

An analysis of data from a pair of major trials indicates use of semaglutide was associated with a reduction in MACE regardless of a patient's baseline triglyceride levels.

An analysis of cardiovascular outcomes from FIDELIO-DKD suggest finerenone use was associated with a 14% reduction in negative cardiovascular outcomes.

In a recent column Gregory Weiss, MD, uses studies from AHA Scientific Sessions 2020 to compare the cost-effectiveness of antihyperglycemic agents for reducing cardiovascular events.

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

The shortage of kidney donors begs a need to consider safe approaches to expand the donor pool.

An analysis from AHA 2020 suggests an HbA1c screening protocol doubled the proportion of patients with known dysglycemia when treating patients with ST-elevation myocardial infarction.

Gregory Weiss, MD, examines 4 studies presented at AHA Scientific Sessions 2020 comparing the cost-effectiveness of antidiabetic agents for reducing cardiovascular events.

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

George Bakris, MD, discusses a study he took part in from AHA 2020 examining the number of diabetic patients meeting the American Diabetes Association's criteria for prescribing an SGLT2 inhibitor.